naltrexone and Schizophrenia

naltrexone has been researched along with Schizophrenia in 61 studies

Research

Studies (61)

Timeframe	Studies, this research(%)	All Research%
pre-1990	17 (27.87)	18.7374
1990's	6 (9.84)	18.2507
2000's	13 (21.31)	29.6817
2010's	7 (11.48)	24.3611
2020's	18 (29.51)	2.80

Authors

Authors	Studies
Kalin, NH	1
Gums, JG; McCoy, L; Monahan, C; Powell, J	1
Elaraby, M; Elkhateeb, AE; Gamal, A; Madian, H; Mazen, DZ; Rasekh, MI; Salem, H; Samir, E	1
Citrome, L; Faden, J; Serdenes, R	1
Corrao, MM; Nelson, LA	1
Gao, J; Li, J; Lu, X; Yang, J	1
Adnan, JA; El Hayek, SA; Geagea, LE; Kobeissy, F; Shatila, MA; Talih, FR	1
Brown, R; Darpo, B; McDonnell, D; Nangia, N; Rege, B; Sun, L; von Moltke, L; Xue, H; Yagoda, S	1
DiPetrillo, L; Jiang, Y; Kunovac, J; McDonnell, D; Potkin, SG; Silverman, BL; Simmons, A	1
Brunette, MF; Citrome, L; Correll, CU; DiPetrillo, L; Green, AI; Jiang, Y; McDonnell, D; O'Malley, SS; Silverman, BL; Simmons, A	1
Arevalo, C; Graham, C; Jiang, Y; McDonnell, D; Simmons, A; Yagoda, S	1
Correll, CU; DiPetrillo, L; Du, Y; Graham, C; Hopkinson, C; Jiang, Y; Kahn, RS; McDonnell, D; Newcomer, JW; Silverman, B; Simmons, A	1
Muvvala, SB; O'Malley, SS; Rosenheck, R	1
Buchanan, RW	1
Likhitsathian, S; Maneeton, B; Maneeton, N; Srisurapanont, M; Suttajit, S	1
Bhupathi, V; DiPetrillo, L; Graham, C; Hopkinson, C; Jiang, Y; Kahn, RS; McDonnell, D; Silverman, BL; Simmons, A; Yagoda, S; Yin, J; Yu, B	1
Mills, R; Rege, B; Sadler, BM; Sun, L	1
Paik, J	1
McDonnell, D; Sun, L; von Moltke, L	1
Correll, CU; DiPetrillo, L; Ehrich, EW; Jiang, Y; Martin, WF; Pathak, S; Silverman, BL; Weiden, PJ	1
Guloksuz, S; Reutenauer, EL; Srihari, VH; Tek, C	1
Borsook, D; Elman, I; Langleben, DD; Simonson, DC; Swift, R; Taveira, TH; Tschibelu, E; Wu, WC; Yamamoto, R	1
Balguerie, K; Coune, F; Jeanblanc, J; Jeanblanc, V; Legastelois, R; Naassila, M	1
Ganguli, R; O'Malley, SS; Ratliff, J; Reutenauer, E; Tek, C	1
Dowling, NA; Lorains, FK; Merkouris, SS	1
Batki, SL; Dimmock, JA; Leontieva, L; Ploutz-Snyder, R	1
Hareyama, N; Ichinose, H; Ikeda, K; Kurokawa, T; Mochizuki, H; Nakajima, M; Nakao, K; Yoshikawa, S	1
Batki, SL; Carey, K; Cavallerano, M; DeRycke, S; Dimmock, J; Leontieva, L; Meszaros, Z; Ploutz-Snyder, R	1
Modesto-Lowe, V; Van Kirk, J	1
Krystal, JH; McHugh-Strong, C; O'Malley, S; Petrakis, IL; Poling, J; Rounsaville, B	1
Adami, H; Avila, M; Hong, LE; Sherr, J; Thaker, GK; Wonodi, I	1
Green, AI	1
Brunette, MF; Drake, RE; Green, AI; Noordsy, DL	1
Carroll, K; Levinson, C; Nich, C; Petrakis, I; Poling, J; Ralevski, E; Rounsaville, B	1
Brunette, MF; Green, AI; Noordsy, DL; O'Keefe, C	1
D'Amelio, R; Falkai, P; Wobrock, T	1
Batki, SL; Dimmock, JA; Gallinger, L; Gately, PW; Leontieva, L; Ploutz-Snyder, R	1
Bakharev, VD; Tikhomirov, SM	1
Volavka, J	1
Buchsbaum, MS; Cappelletti, J; Davis, GC; Holcomb, HH; Reus, VI; Silberman, E	1
Martin, WR; McNicholas, LF	1
Anderson, B; Koz, G; Volavka, J	1
Gerner, RH; Gitlin, MJ; Rosenblatt, M	1
Ban, T; Berney, S; Ragheb, M	1
Buchsbaum, MS; Bunney, WE; Davis, GC	1
Thompson, DF; Welch, EB	1
Kelsoe, JR; Konicki, PE; Pato, C; Pickar, D; Rapaport, MH; Wolkowitz, O	1
Alam, MY; Becker, JA; Goldman, MB; Luchins, DJ	1
Chelli, F; Cotani, P; Giordano, A; Marchesi, GF; Santone, G	2
Charney, DS; Glazer, WM; Heninger, GR; Krystal, JH; Petrakis, IL; Price, LH; Sernyak, MJ; Woods, SW	1
Dhopesh, V; Fudala, PJ; Yu, E	1
Mulé, SJ; Verebey, K	1
Akil, H; Barchas, JD; Berger, PA; Watson, SJ	1
Mackay, AV	1
Buchsbaum, MS; Bunney, WE; Davis, GC; van Kammen, DP	1
Julius, DA	1
Gitlin, M; Rosenblatt, M	1
Gallant, DM; Mielke, DH	1
Gabel, T; Malcolm, R; Morton, A	1
Schulz, SC; van Kammen, DP	1

Reviews

15 review(s) available for naltrexone and Schizophrenia

Article	Year
Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia. The Annals of pharmacotherapy, 2022, Volume: 56, Issue:9 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Naltrexone; Olanzapine; Schizophrenia	2022
Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used? Expert review of neurotherapeutics, 2022, Volume: 22, Issue:5 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Tablets; Weight Gain	2022
Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain. CNS drugs, 2022, Volume: 36, Issue:6 Topics: Analgesics, Opioid; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Naltrexone; Olanzapine; Schizophrenia; Weight Gain	2022
Is there a therapeutic potential in combining bupropion and naltrexone in schizophrenia? Expert review of neurotherapeutics, 2022, Volume: 22, Issue:9 Topics: Bupropion; Dopamine; Humans; Naltrexone; Schizophrenia	2022
A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine. Scientific reports, 2021, 04-07, Volume: 11, Issue:1 Topics: Antipsychotic Agents; Cardiometabolic Risk Factors; Drug Therapy, Combination; Female; Humans; Male; Metabolic Syndrome; Naltrexone; Olanzapine; Schizophrenia; Weight Gain	2021
Olanzapine/Samidorphan: First Approval. Drugs, 2021, Volume: 81, Issue:12 Topics: Antipsychotic Agents; Bipolar Disorder; Drug Combinations; Humans; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Weight Gain	2021
Interventions for comorbid problem gambling and psychiatric disorders: Advancing a developing field of research. Addictive behaviors, 2016, Volume: 58 Topics: Acetylcysteine; Antimanic Agents; Antipsychotic Agents; Anxiety Disorders; Behavior Therapy; Bipolar Disorder; Citalopram; Cognitive Behavioral Therapy; Comorbidity; Free Radical Scavengers; Gambling; Humans; Lithium Compounds; Mental Disorders; Motivational Interviewing; Naltrexone; Narcotic Antagonists; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Tobacco Use Disorder	2016
Clinical uses of naltrexone: a review of the evidence. Experimental and clinical psychopharmacology, 2002, Volume: 10, Issue:3 Topics: Alcoholism; Animals; Behavior, Addictive; Cocaine-Related Disorders; Feeding and Eating Disorders; Humans; Naltrexone; Narcotic Antagonists; Obsessive-Compulsive Disorder; Opioid-Related Disorders; Schizophrenia; Self-Injurious Behavior; Substance-Related Disorders; Tobacco Use Disorder	2002
Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches. The Journal of clinical psychiatry, 2006, Volume: 67 Suppl 7 Topics: Alcohol Deterrents; Alcoholism; Antipsychotic Agents; Clozapine; Comorbidity; Diagnosis, Dual (Psychiatry); Disulfiram; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Schizophrenia; Substance-Related Disorders; Treatment Outcome	2006
Substance abuse and schizophrenia: pharmacotherapeutic intervention. Journal of substance abuse treatment, 2008, Volume: 34, Issue:1 Topics: Acamprosate; Alcohol Deterrents; Antipsychotic Agents; Clozapine; Disulfiram; Drug Interactions; Humans; Naltrexone; Narcotics; Schizophrenia; Substance-Related Disorders; Taurine	2008
[Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review]. Der Nervenarzt, 2008, Volume: 79, Issue:1 Topics: Alcohol Deterrents; Alcoholism; Algorithms; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Clinical Trials as Topic; Comorbidity; Diagnosis, Dual (Psychiatry); Disulfiram; Dose-Response Relationship, Drug; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Naltrexone; Narcotic Antagonists; Schizophrenia; Substance-Related Disorders	2008
[Neuropeptide role in the etiology, pathogenesis and clinical aspects of mental diseases]. Sovetskaia meditsina, 1984, Issue:6 Topics: Animals; Anticonvulsants; Antipsychotic Agents; Depressive Disorder; Drug Therapy, Combination; Endorphins; Enkephalins; Humans; Mental Disorders; Naloxone; Naltrexone; Nerve Tissue Proteins; Pituitary Hormones; Psychotropic Drugs; Schizophrenia; Substance-Related Disorders; Vasopressins	1984
New and experimental therapeutic roles for naloxone and related opioid antagonists. Drugs, 1984, Volume: 27, Issue:1 Topics: Alcohol Deterrents; Animals; Bipolar Disorder; Blood Pressure; Brain Ischemia; Clinical Trials as Topic; Humans; Lung Diseases, Obstructive; Naloxone; Naltrexone; Narcotic Antagonists; Receptors, Opioid; Respiration; Schizophrenia; Shock; Spinal Injuries	1984
Opiate antagonists for the treatment of schizophrenia. Journal of clinical pharmacy and therapeutics, 1994, Volume: 19, Issue:5 Topics: Hallucinations; Humans; Naloxone; Naltrexone; Schizophrenia	1994
Some observations on the opiate peptides and schizophrenia. Archives of general psychiatry, 1979, Volume: 36, Issue:1 Topics: Administration, Oral; Brain; Double-Blind Method; Endorphins; Forecasting; Humans; Naloxone; Naltrexone; Receptors, Opioid; Renal Dialysis; Schizophrenia	1979

Trials

23 trial(s) available for naltrexone and Schizophrenia

Article	Year
Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study. Progress in neuro-psychopharmacology & biological psychiatry, 2020, 06-08, Volume: 100 Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Heart Rate; Humans; Male; Middle Aged; Moxifloxacin; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia	2020
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study. The Journal of clinical psychiatry, 2020, 03-03, Volume: 81, Issue:2 Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Olanzapine; Outcome Assessment, Health Care; Schizophrenia; Symptom Flare Up	2020
Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial. The Journal of clinical psychiatry, 2020, 03-10, Volume: 81, Issue:2 Topics: Adult; Alcoholism; Antipsychotic Agents; Comorbidity; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Olanzapine; Outcome Assessment, Health Care; Schizophrenia	2020
Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study. CNS spectrums, 2021, Volume: 26, Issue:4 Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Olanzapine; Schizophrenia; Treatment Outcome	2021
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. The American journal of psychiatry, 2020, 12-01, Volume: 177, Issue:12 Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Weight Gain; Young Adult	2020
A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension. Schizophrenia research, 2021, Volume: 232 Topics: Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Humans; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Treatment Outcome	2021
Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia. Clinical therapeutics, 2018, Volume: 40, Issue:11 Topics: Administration, Oral; Adult; Antipsychotic Agents; Chromatography, Liquid; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Olanzapine; Schizophrenia; Tandem Mass Spectrometry; Weight Gain	2018
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia. The American journal of psychiatry, 2019, 06-01, Volume: 176, Issue:6 Topics: Adult; Antipsychotic Agents; Constipation; Dizziness; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Least-Squares Analysis; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Sleepiness; Weight Gain	2019
Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC psychiatry, 2013, Jun-27, Volume: 13 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Clinical Protocols; Double-Blind Method; Female; Humans; Male; Mental Disorders; Middle Aged; Naltrexone; Narcotic Antagonists; Overweight; Psychotic Disorders; Research Design; Schizophrenia; Weight Gain; Weight Loss	2013
The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study. Journal of psychopharmacology (Oxford, England), 2014, Volume: 28, Issue:4 Topics: Adipose Tissue; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Female; Humans; Insulin Resistance; Lipids; Liver Function Tests; Male; Middle Aged; Naltrexone; Olanzapine; Pilot Projects; Psychotic Disorders; Schizophrenia; Young Adult	2014
A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept. Journal of clinical psychopharmacology, 2014, Volume: 34, Issue:5 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cholesterol; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Pilot Projects; Psychotic Disorders; Quality of Life; Schizophrenia; Triglycerides; Weight Gain; Young Adult	2014
Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology, 2004, Volume: 172, Issue:3 Topics: Alcoholism; Comorbidity; Double-Blind Method; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; New England; Schizophrenia; Severity of Illness Index; Treatment Outcome	2004
Naltrexone treatment of tardive dyskinesia in patients with schizophrenia. Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:4 Topics: Adult; Analysis of Variance; Antipsychotic Agents; Clonazepam; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Naltrexone; Schizophrenia	2004
Naltrexone and disulfiram in patients with alcohol dependence and current depression. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:2 Topics: Alcohol Deterrents; Alcoholism; Bipolar Disorder; Cocaine-Related Disorders; Comorbidity; Connecticut; Depressive Disorder, Major; Disulfiram; Double-Blind Method; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Gastrointestinal Diseases; Humans; Male; Massachusetts; Middle Aged; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Stress Disorders, Post-Traumatic; Treatment Outcome; Veterans	2007
Action of naloxone and naltrexone in different types of psychoses. Modern problems of pharmacopsychiatry, 1981, Volume: 17 Topics: Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Endorphins; Humans; Naloxone; Naltrexone; Psychotic Disorders; Receptors, Opioid; Schizophrenia	1981
New and experimental therapeutic roles for naloxone and related opioid antagonists. Drugs, 1984, Volume: 27, Issue:1 Topics: Alcohol Deterrents; Animals; Bipolar Disorder; Blood Pressure; Brain Ischemia; Clinical Trials as Topic; Humans; Lung Diseases, Obstructive; Naloxone; Naltrexone; Narcotic Antagonists; Receptors, Opioid; Respiration; Schizophrenia; Shock; Spinal Injuries	1984
Naloxone and naltrexone in mental illness and tardive dyskinesia. Annals of the New York Academy of Sciences, 1982, Volume: 398 Topics: Animals; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Endorphins; Humans; Mood Disorders; Naloxone; Naltrexone; Rats; Schizophrenia	1982
Assessment of naltrexone in the treatment of schizophrenia. Psychopharmacology, 1981, Volume: 74, Issue:1 Topics: Adult; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Male; Naloxone; Naltrexone; Schizophrenia	1981
Naltrexone in chronic schizophrenia. Results of a clinical trial. International pharmacopsychiatry, 1980, Volume: 15, Issue:1 Topics: Adult; Chronic Disease; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Naloxone; Naltrexone; Psychiatric Status Rating Scales; Schizophrenia	1980
Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 1993, Volume: 9, Issue:2 Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydrocortisone; Male; Methoxyhydroxyphenylglycol; Naltrexone; Narcotic Antagonists; Prolactin; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology	1993
The therapeutic role of naltrexone in negative symptom schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry, 1995, Volume: 19, Issue:8 Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	1995
Naltrexone augmentation of neuroleptics in schizophrenia. Journal of clinical psychopharmacology, 1998, Volume: 18, Issue:3 Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Double-Blind Method; Drug Therapy, Combination; Female; Fluphenazine; Haloperidol; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Schizophrenia	1998
Naltrexone in chronic negative schizophrenia. Clinical neuropharmacology, 1992, Volume: 15 Suppl 1 Pt A Topics: Adult; Chronic Disease; Double-Blind Method; Female; Humans; Male; Naltrexone; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology	1992

Other Studies

24 other study(ies) available for naltrexone and Schizophrenia

Article	Year
Insights Into Improving Clinical Outcomes Across Psychiatric Disorders and Medical Comorbidities. The American journal of psychiatry, 2021, 09-01, Volume: 178, Issue:9 Topics: Alcoholism; Anorexia Nervosa; Attention Deficit Disorder with Hyperactivity; Comorbidity; Humans; Mental Disorders; Methadone; Naltrexone; Narcotics; Patient Outcome Assessment; Schizophrenia; Smoking; Varenicline	2021
Spectrofluorimetric first derivative synchronous approach for determination of olanzapine and samidorphan used for treatment of schizophrenia in pharmaceutical formulations and human plasma. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2022, Jun-05, Volume: 274 Topics: Antipsychotic Agents; Drug Compounding; Humans; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Spectrometry, Fluorescence; Tablets	2022
Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder. Expert review of clinical pharmacology, 2022, Volume: 15, Issue:9 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Weight Gain	2022
Multiple Psychiatric Morbidity and Continued Use of Naltrexone for Alcohol Use Disorder. The American journal on addictions, 2021, Volume: 30, Issue:1 Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Ambulatory Care; Depressive Disorder, Major; Female; Hospitalization; Humans; Ill-Housed Persons; Male; Mental Health Services; Middle Aged; Morbidity; Naltrexone; Psychotherapy; Psychotropic Drugs; Schizophrenia; Socioeconomic Factors; United States; United States Department of Veterans Affairs; Veterans	2021
How Much of an Advance Is the Addition of Samidorphan to Olanzapine? The American journal of psychiatry, 2020, 12-01, Volume: 177, Issue:12 Topics: Antipsychotic Agents; Humans; Naltrexone; Olanzapine; Schizophrenia; Weight Gain	2020
Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia. Journal of clinical pharmacology, 2021, Volume: 61, Issue:11 Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Body Weight; Cigarette Smoking; Cytochrome P-450 CYP3A; Drug Combinations; Female; Food-Drug Interactions; Humans; Liver Failure; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Olanzapine; Racial Groups; Renal Insufficiency; Rifampin; Schizophrenia; Sex Factors; Young Adult	2021
Light alcohol intake during adolescence induces alcohol addiction in a neurodevelopmental model of schizophrenia. Addiction biology, 2015, Volume: 20, Issue:3 Topics: Alcohol Drinking; Alcoholism; Animals; Animals, Newborn; Central Nervous System Depressants; Conditioning, Operant; Disease Models, Animal; Drug-Seeking Behavior; Ethanol; Hippocampus; Male; Naltrexone; Narcotic Antagonists; Rats, Sprague-Dawley; Schizophrenia	2015
Negative symptoms are associated with less alcohol use, craving, and "high" in alcohol dependent patients with schizophrenia. Schizophrenia research, 2008, Volume: 105, Issue:1-3 Topics: Adult; Alcohol Drinking; Alcoholism; Behavior, Addictive; Cocaine-Related Disorders; Cognition Disorders; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Euphoria; Female; Humans; Male; Marijuana Abuse; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index	2008
Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models. European journal of pharmacology, 2009, Mar-15, Volume: 606, Issue:1-3 Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine; Extracellular Space; Hyperkinesis; Male; Morphinans; Naltrexone; Phencyclidine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Schizophrenia; Serotonin; Spiro Compounds	2009
Patient and provider attitudes towards monitored naltrexone treatment of alcohol dependence in schizophrenia. The American journal of drug and alcohol abuse, 2009, Volume: 35, Issue:5 Topics: Adult; Alcohol-Related Disorders; Attitude of Health Personnel; Clinical Trials as Topic; Counseling; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Patient Satisfaction; Schizophrenia; Substance Abuse Treatment Centers; Surveys and Questionnaires; Treatment Outcome	2009
Schizophrenia and co-occurring substance use disorder. The American journal of psychiatry, 2007, Volume: 164, Issue:3 Topics: Acamprosate; Adult; Alcohol-Related Disorders; Antipsychotic Agents; Comorbidity; Diagnosis, Dual (Psychiatry); Disulfiram; Humans; Ill-Housed Persons; Male; Naltrexone; Schizophrenia; Substance-Related Disorders; Taurine	2007
Voucher-based incentives for naltrexone treatment attendance in schizophrenia and alcohol use disorders. Psychiatric services (Washington, D.C.), 2008, Volume: 59, Issue:3 Topics: Adult; Alcoholism; Female; Humans; Male; Motivation; Naltrexone; Narcotics; Schizophrenia; Token Economy	2008
Role of opioid peptides in disorders of attention in psychopathology. Annals of the New York Academy of Sciences, 1982, Volume: 398 Topics: Adrenocorticotropic Hormone; Adult; Attention; Brain Mapping; Endorphins; Evoked Potentials, Auditory; Evoked Potentials, Somatosensory; Evoked Potentials, Visual; Female; Humans; Male; Naltrexone; Pain; Peptide Fragments; Schizophrenia; Schizophrenic Psychology	1982
Alterations of evoked potentials link research in attention dysfunction to peptide response symptoms of schizophrenia. Advances in biochemical psychopharmacology, 1980, Volume: 22 Topics: Acoustic Stimulation; Attention; Endorphins; Evoked Potentials; Humans; Morphine; Naltrexone; Pain; Peptides; Schizophrenia; Schizophrenic Psychology	1980
Effects of naltrexone on mannerisms and water imbalance in polydipsic schizophrenics: a pilot study. Schizophrenia research, 1995, Volume: 17, Issue:3 Topics: Adult; Antipsychotic Agents; Drinking; Drug Therapy, Combination; Humans; Hyponatremia; Male; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Stereotyped Behavior; Treatment Outcome; Water-Electrolyte Balance; Weight Gain	1995
Conservative management with naltrexone of an iatrogenic methadone overdose in an opiate-naive patient. Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:2 Topics: Alcoholism; Cocaine-Related Disorders; Diagnosis, Dual (Psychiatry); Drug Overdose; Humans; Male; Medication Errors; Methadone; Middle Aged; Naltrexone; Schizophrenia	2002
Naltrexone, 6 beta-naltrexol and 2-hydroxy-3-methoxy-6 beta-naltrexol plasma levels in schizophrenic patients after large oral doses of naltrexone. NIDA research monograph, 1979, Volume: 27 Topics: Humans; Middle Aged; Naloxone; Naltrexone; Schizophrenia	1979
Psychiatric implications of endorphin research. The British journal of psychiatry : the journal of mental science, 1979, Volume: 135 Topics: Animals; Avoidance Learning; Behavior, Animal; Chronic Disease; Endorphins; Humans; Mental Disorders; Naloxone; Naltrexone; Rats; Receptors, Opioid; Schizophrenia	1979
Analgesia to pain stimuli in schizophrenics and its reversal by naltrexone. Psychiatry research, 1979, Volume: 1, Issue:1 Topics: Adult; Electric Stimulation; Evoked Potentials; Female; Humans; Male; Naloxone; Naltrexone; Pain; Schizophrenia	1979
Withdrawal from endogenous opiates. The American journal of psychiatry, 1979, Volume: 136, Issue:3 Topics: Endorphins; Humans; Naloxone; Naltrexone; Schizophrenia; Substance Withdrawal Syndrome	1979
Possible withdrawal from endogeneous opiates in schizophrenics. The American journal of psychiatry, 1978, Volume: 135, Issue:3 Topics: Female; Humans; Male; Naloxone; Naltrexone; Schizophrenia; Substance Withdrawal Syndrome; Time Factors	1978
An oral opiate antagonist in chronic schizophrenia: a pilot study. The American journal of psychiatry, 1977, Volume: 134, Issue:12 Topics: Administration, Oral; Adult; Drug Evaluation; Female; Humans; Male; Middle Aged; Naloxone; Naltrexone; Pilot Projects; Schizophrenia	1977
Idiosyncratic reaction to naltrexone augmented by thioridazine. The American journal of psychiatry, 1988, Volume: 145, Issue:6 Topics: Adult; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Male; Naltrexone; Opioid-Related Disorders; Schizophrenia; Sleep Stages; Thioridazine	1988
d-Amphetamine raises cortisol levels in schizophrenic patients with and without chronic naltrexone pretreatment. Journal of neural transmission, 1985, Volume: 64, Issue:1 Topics: Adult; Circadian Rhythm; Dextroamphetamine; Female; Humans; Hydrocortisone; Male; Naltrexone; Premedication; Schizophrenia	1985